Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The chemopreventative effects of dithiolethione compounds are attributed to their activation of antioxidant response elements (AREs) by reacting with the Nrf2/Keap1 protein complex. In this study, we show antiproliferative effects of the dithiolethione compound ACS-1 in human cancer cell lines (A549 and MDA-MB-231) by increasing the activity of the tumor suppressor protein phoshatase 2A (PP2A). ACS-1 inhibited epidermal growth factor (EGF)-induced cellular proliferation in a concentration- and time-dependent manner. Akt activation, as determined by serine-473 phosphorylation, was inhibited by ACS-1 in cells stimulated with either EGF or fibronectin. Furthermore, ACS-1 inhibited mammalian target of rapamycin signaling and decreased c-myc protein levels. ACS-1 did not proximally alter EGF receptor or integrin signaling, but caused a concentration-dependent increase in PP2A activity. The effect of ACS-1 on Akt activation was not observed in the presence of the PP2A inhibitor okadaic acid. ACS-1 effects on PP2A activity were independent of ARE activation and cAMP formation. In addition to ACS-1, other dithiolethione compounds showed similar effects in reducing Akt activation, suggesting that this class of compounds may have other effects beyond chemoprevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation
Chen, J., Martin, B. L., & Brautigan, D. L. (1992) · Science · doi:10.1126/science.1325671 · Cited by 601 · cited 2×
“Additionally, altering the phosphorylation and methylation status of the PP2A subunits can further modulate PP2A activity (Chen et al., 1992; Longin et al., 2007; Xing et al., 2008).”
BackgroundResultArnold, H. K., & Sears, R. C. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2832-2844.2006 · Cited by 251 · cited 2×
“In addition to altering Akt signaling, c-myc is a substrate for PP2A phosphatase activity and negatively regulates c-myc protein levels by the induction of ubiquitin dependent proteolysis (Arnold and Sears, 2008; Arnold and Sears, 2006; Trotta et al., 2007).”
BackgroundStructural mechanism of demethylation and inactivation of protein phosphatase 2A
Xing, Y., Li, Z., Chen, Y., Stock, J. B., Jeffrey, P. D., & Shi, Y. (2008) · Cell · doi:10.1016/j.cell.2008.02.041 · Cited by 206 · cited 2×
“Additionally, altering the phosphorylation and methylation status of the PP2A subunits can further modulate PP2A activity (Chen et al., 1992; Longin et al., 2007; Xing et al., 2008).”
BackgroundLongin, S., Zwaenepoel, K., Louis, J. V., Dilworth, S., Goris, J., & Janssens, V. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704059200 · Cited by 184
Arnold, H. K., & Sears, R. C. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9128-9 · Cited by 111
Rocher, G., Letourneux, C., Lenormand, P., & Porteu, F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609712200 · Cited by 87 · cited 2×
“A major endogenous negative regulator of Akt signaling is PP2A (Andjelkovic et al., 1996; Sato et al., 2000; Resjö et al., 2002; Ugi et al., 2004; Rocher et al., 2007).”
Background
Cited by
Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy
Switzer, C. H., Cheng, R. Y. S., Vitek, T. M., Christensen, D. J., Wink, D. A., & Vitek, M. P. (2011) · Oncogene · doi:10.1038/onc.2010.622 · Cited by 171
Self-citationStructure, Regulation, and Pharmacological Modulation of PP2A Phosphatases
Lambrecht, C., Haesen, D., Sents, W., Ivanova, E., & Janssens, V. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-562-0_17 · Cited by 140
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Switzer, C. H., Glynn, S. A., Ridnour, L. A., Cheng, R. Y.-S., Vitek, M. P., Ambs, S., & Wink, D. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.07.001 · Cited by 74
“Small molecule agents have been found that increase PP2A phosphatase activity in cancer cells [86-88].”
InfluentialNitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation
Ridnour, L. A., Barasch, K. M., Windhausen, A. N., Dorsey, T. H., Lizardo, M. M., Yfantis, H. G., Lee, D. H., Switzer, C. H., Cheng, R. Y. S., Heinecke, J. L., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044081 · Cited by 71
“pathways including chemopreventive dithiolethiones, which are clinically available [35,36].”
BackgroundSelf-citation
Metadata
- Authors
- Switzer, C. H., Ridnour, L. A., Cheng, R. Y. S., Sparatore, A., Del Soldato, P., Moody, T. W., Vitek, M. P., Roberts, D. D., & Wink, D. A.
- Venue
- Oncogene
- Published
- 2009-08-24
- Volume
- 28
- Issue
- 43
- Pages
- 3837-3846
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2089025540
- Cited by
- 46
- References
- 7
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.